Centers | ||
Therapeutic Accelerator Program (TAP) | Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | Drug Discovery Core |
Test |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
The Drug Discovery Core at the University of Utah is an established Service/Recharge center that provides compound collections for screening by University of Utah Faculty. Our mission is to provide customers low-cost and efficient access to chemical... |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Bayer and UCSF Enter into a 10year Research & Development PartnershipBayer and University of California, San Francisco (UCSF) have signed a 10year master research and development agreement. The agreement provides a broad template for collaboration between the two groups around common areas of research interest... View all Evotec and Yale University to collaborate on cancer therapyEvotec announced a research collaboration, TargetDBR (DNA Break Repair), with the laboratories of Prof. Peter Glazer and Prof. Ranjit Bindra at Yale School of Medicine. The objective of this collaboration is to identify novel mechanisms, targets and... View all |
No EVENTS for listing |
No Job Posts |


